These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28587526)

  • 1. Optimal teicoplanin dosage regimens for methicillin-resistant Staphylococcus aureus infections in endocarditis patients and renal failure patients.
    Li N; Zhu L; Xu G; Ge T; Qi F; Li M
    J Chemother; 2017 Dec; 29(6):358-364. PubMed ID: 28587526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin-resistant Staphylococcus aureus.
    Hagihara M; Umemura T; Kimura M; Mori T; Hasegawa T; Mikamo H
    J Infect Chemother; 2012 Feb; 18(1):10-6. PubMed ID: 21710160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of right-sided native valve methicillin-resistant Staphylococcus aureus endocarditis and septicaemia with teicoplanin and rifampicin: a case report.
    Saravu K; Mukhopadhyay C; Satyanarayanan V; Pai A; Komaranchath AS; Munim F; Shastry BA; Tom D
    Scand J Infect Dis; 2012 Jul; 44(7):544-7. PubMed ID: 22385220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose regimen to achieve novel target trough concentration in teicoplanin.
    Ueda T; Takesue Y; Nakajima K; Ichki K; Wada Y; Komatsu M; Tsuchida T; Takahashi Y; Ishihara M; Kimura T; Uchino M; Ikeuchi H
    J Infect Chemother; 2014 Jan; 20(1):43-7. PubMed ID: 24462424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model-based dosing optimization and therapeutic drug monitoring practices of teicoplanin in patients with complicated or non-complicated methicillin-resistant staphylococcus aureus infection.
    Zhang XS; Chen YL; Wang YZ; Chen C; Chen YJ; Xu FM; Dai Y; Shi DW; Lin GY; Yu XB; Xiang DZ; Zhang CH
    Br J Clin Pharmacol; 2024 Feb; 90(2):452-462. PubMed ID: 37749762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of initial loading procedure for teicoplanin in critically ill patients with severe infections.
    Matsumoto K; Kanazawa N; Watanabe E; Yokoyama Y; Fukamizu T; Shimodozono Y; Maeda C; Yasuda T; Kakihana Y; Ikawa K; Morikawa N; Takeda Y
    Biol Pharm Bull; 2013; 36(6):1024-6. PubMed ID: 23727923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections.
    Matsumoto K; Kanazawa N; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    J Infect Chemother; 2010 Jun; 16(3):193-9. PubMed ID: 20195882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of individual adjustment of initial loading dosage of teicoplanin based on population pharmacokinetics.
    Niwa T; Imanishi Y; Ohmori T; Matsuura K; Murakami N; Itoh Y
    Int J Antimicrob Agents; 2010 May; 35(5):507-10. PubMed ID: 20185275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction.
    Ueda T; Takesue Y; Nakajima K; Ichiki K; Doita A; Wada Y; Tsuchida T; Takahashi Y; Ishihara M; Ikeuchi H; Uchino M; Kimura T
    Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1501-9. PubMed ID: 27278654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of factors associated with the achievement of an optimal teicoplanin trough concentration
.
    Takechi K; Yanagawa H; Zamami Y; Ishizawa K; Tanaka A; Araki H
    Int J Clin Pharmacol Ther; 2017 Aug; 55(8):672-677. PubMed ID: 28655381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of infective endocarditis caused by methicillin-resistant Staphylococcus aureus: teicoplanin versus vancomycin in a retrospective study.
    Huang JH; Hsu RB
    Scand J Infect Dis; 2008; 40(6-7):462-7. PubMed ID: 18584532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days.
    Ueda T; Takesue Y; Nakajima K; Ichiki K; Ishikawa K; Takai Y; Yamada K; Tsuchida T; Otani N; Takahashi Y; Ishihara M; Takubo S; Ikeuchi H; Uchino M; Kimura T
    BMC Pharmacol Toxicol; 2020 Jul; 21(1):50. PubMed ID: 32641110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic and pharmacodynamic analyses of teicoplanin in Japanese patients with systemic MRSA infection.
    Ogawa R; Kobayashi S; Sasaki Y; Makimura M; Echizen H
    Int J Clin Pharmacol Ther; 2013 May; 51(5):357-66. PubMed ID: 23458228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of teicoplanin in hospitalized elderly patients using cystatin C as an indicator of renal function.
    Kasai H; Tsuji Y; Hiraki Y; Tsuruyama M; To H; Yamamoto Y
    J Infect Chemother; 2018 Apr; 24(4):284-291. PubMed ID: 29292178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level.
    Sato M; Chida K; Suda T; Muramatsu H; Suzuki Y; Hashimoto H; Gemma H; Nakamura H
    J Infect Chemother; 2006 Aug; 12(4):185-9. PubMed ID: 16944256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of teicoplanin dosing designs to achieve a new target trough concentration.
    Ueda T; Takesue Y; Nakajima K; Ichki K; Wada Y; Tsuchida T; Takahashi Y; Ishihara M; Tatsumi S; Kimura T; Ikeuchi H; Uchino M
    J Infect Chemother; 2012 Jun; 18(3):296-302. PubMed ID: 22065089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication.
    Kanazawa N; Matsumoto K; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    J Infect Chemother; 2011 Apr; 17(2):297-300. PubMed ID: 20714913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis.
    Chen CY; Xie M; Gong J; Yu N; Wei R; Lei LL; Zhao SM; Li RM; Dong X; Zhang XL; Zhou Y; Li SL; Cui YM
    Front Pharmacol; 2023; 14():1132367. PubMed ID: 37188268
    [No Abstract]   [Full Text] [Related]  

  • 19. Population pharmacokinetics of teicoplanin in children.
    Ramos-Martín V; Paulus S; Siner S; Scott E; Padmore K; Newland P; Drew RJ; Felton TW; Docobo-Pérez F; Pizer B; Pea F; Peak M; Turner MA; Beresford MW; Hope WW
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6920-7. PubMed ID: 25224001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hospital Pharmacometrics for Optimal Individual Administration of Antimicrobial Agents for Anti-methicillin-resistant Staphylococcus aureus Infected Patients.
    Tsuji Y
    Biol Pharm Bull; 2021; 44(9):1174-1183. PubMed ID: 34471044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.